RXRuolan Xia

Ruolan Xia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruolan Xia has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Maosen Xu

    Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, People’s Republic of China

    2 shared publications
  • Xiawei Wei

    Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, People’s Republic of China

    2 shared publications
  • Yuquan Wei

    Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Tao Zhang

    State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610041, China

    1 shared publication
  • Xingchen Peng

    Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, China

    1 shared publication

Latest Publications

  • Open Access

    Mucosal immunity: mechanism and application in cancer immunotherapy

    by Maosen Xu, Ruolan Xia, Yuquan Wei, Xingchen Peng, Xiawei Wei

  • Top Cited Papers
    Open Access

    Targeting the tumor stroma for cancer therapy

    by Maosen Xu, Tao Zhang, Ruolan Xia, Yuquan Wei, Xiawei Wei

    Tumors are comprised of both cancer cells and surrounding stromal components. As an essential part of the tumor microenvironment, the tumor stroma is highly dynamic, heterogeneous and commonly tumor-type specific, and it mainly includes noncellular compositions such as the extracellular matrix and the unique cancer-associated vascular system as well as a wide variety of cellular components including activated cancer-associated fibroblasts, mesenchymal stromal cells, pericytes. All these elements operate with each other in a coordinated fashion and collectively promote cancer initiation, progression, metastasis and therapeutic resistance. Over the past few decades, numerous studies have been conducted to study the interaction and crosstalk between stromal components and neoplastic cells. Meanwhile, we have also witnessed an exponential increase in the investigation and recognition of the critical roles of tumor stroma in solid tumors. A series of clinical trials targeting the tumor stroma have been launched continually. In this review, we introduce and discuss current advances in the understanding of various stromal elements and their roles in cancers. We also elaborate on potential novel approaches for tumor-stroma-based therapeutic targeting, with the aim to promote the leap from bench to bedside.